True, there was a post saying that as goes sari so
Post# of 148181
Just saying keep tocil somewhere on your list of possibles. We saw it on a Yale decision tree a week or so back. And the trial data timing is so spot on.
Regeneron (given recent coverage, maybe a higher likelihood) and Barti both also seem quite reasonable, among others.